Radioembolization for colorectal liver metastases

doi:10.1017/CBO9781107338555.018

18 - Radioembolization for colorectal liver metastases

from Section IV - Organ-specific cancers – liver metastases

Published online by Cambridge University Press: 05 September 2016

Lourens Bester ,

Baerbel Meteling and

David Boshell

Edited by

Jean-Francois H. Geschwind and

Michael C. Soulen

Show author details

Lourens Bester: Affiliation:
University of New South Wales
Baerbel Meteling: Affiliation:
University of New South Wales
David Boshell: Affiliation:
University of New South Wales
Jean-Francois H. Geschwind: Affiliation:
Yale University School of Medicine, Connecticut
Michael C. Soulen: Affiliation:
Department of Radiology, University of Pennsylvania Hospital, Philadelphia

Book contents

Get access

Summary

Radioembolization is internal brachytherapy that delivers high doses of beta radiation locally into liver tumors. Glass or resin microspheres incorporating the radioactive isotope yttrium-90 (90Y) are directly injected into the hepatic arteries feeding the tumor. Resin microspheres differ from glass microspheres in that they have lower specific gravity, lower activity, and a higher number of particles. As part of the selection process for radioembolization, clinical history, laboratory values and performance status are obtained and patients are initially evaluated and staged using cross-sectional imaging techniques. Pretreatment imaging workup is required to visualize the entire liver vasculature and flow patterns, including the detection and selective occlusion of vessels which might allow 90Y microspheres to enter extrahepatic tissues. During the treatment procedure, microspheres are injected through a temporary angiographic catheter placed percutaneously via the femoral or brachial artery. Clinical toxicity is assessed at the time of treatment and approximately 2–3 months thereafter. A comprehensive review of the technical and methodological considerations in 90Y has been previously published.

Two radioembolic products are commercially available. Thera-Sphere (glass microspheres) gained a Humanitarian Device Exemption from the Food and Drug Administration (FDA) in 1999 for the treatment of unresectable hepatocellular carcinoma (HCC) in patients with or without portal vein thrombosis (PVT) who can have appropriately positioned hepatic arterial catheters. SIR-Spheres (resin microspheres) gained full premarketing approval from the FDA in 2002 for the treatment of unresectable colorectal liver metastases in conjunction with intrahepatic floxuridine (FUDR).

Both devices have approval for treatment of liver cancer in Europe and various Asian countries.

Introduction

Despite advances in systemic chemotherapy and monoclonal antibodies, the liver usually remains the site of tumor resistance and ultimately the patient's death. Approximately 60% of patients diagnosed with colorectal carcinoma eventually develop hepatic metastases, with the liver as the dominant site of disease. Complete surgical resection remains the best option for a cure. However, surgical resection is currently only possible in less than 20% of patients with metastatic colorectal cancer. Further, about 60–90% of patients treated with neoadjuvant chemotherapy and liver resection will experience a recurrence of their liver tumors. In patients with unresectable liver metastases, with or without extrahepatic disease, systemic chemotherapy is still the standard of care for first- and second-line treatment.

Information

Type: Chapter
Information: Interventional Oncology
Principles and Practice of Image-Guided Cancer Therapy
, pp. 158 - 164

DOI: https://doi.org/10.1017/CBO9781107338555.018 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

1. Salem, R, Thurston, KG. Radioembolization with 90yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006; 17 (8): 1251–1278.Google Scholar

2. Salem, R, Thurston, KG. Radioembolization with 90yttrium microspheres: A state-of-the-art brachy-therapy treatment for primary and secondary liver malignancies: Part 2: Special topics. J Vasc Interv Radiol 2006; 17 (9): 1425–1439.Google Scholar

3. Salem, R, Thurston, KG. Radioembolization with yttrium-90 microspheres: A state-of-the-art brachy-therapy treatment for primary and secondary liver malignancies: Part 3: Comprehensive literature review and future direction. J Vasc Interv Radiol 2006; 17 (10): 1571–1593.Google Scholar

4. TheraSphere Yttrium-90 microspheres package insert. Kanata, Canada: MDS Nordion; 2004.

5. SIR-Spheres Yttrium-90 microspheres package insert. Lane Cove, Australia: SIRTeX Medical; 2004.

6. Sasson, AR, Sigurdson, ER. Surgical treatment of liver metastases. Semin Oncol 2002; 29 (2): 107–118.Google Scholar

7. Baker, M, Pelley, R. Hepatic metastases: Basic principles and implications for radiologists. Radiology 1995; 197 (2): 329–337.Google Scholar

8. Nordlinger, B, Cutsem, E Van, Rougier, P, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007; 43: 2037–2045.Google Scholar

9. Messersmith, W, Laheru, D, Hidalgo, M. Recent advances in the pharmacological treatment of colorectal cancer. Expert Opin Investig Drugs 2003; 12 (3): 423–434.Google Scholar

10. Mulcahy, MF, Benson, AB, 3rd. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 2005; 5 (7): 997–1005.Google Scholar

11. Hoff, PM. Future directions in the use of antiangiogenic agents in patients with colorectal cancer. Semin Oncol 2004; 31 (6 Suppl 17): 17–21.Google Scholar

12. Yu, AS, Keeffe, EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003; 3 (1): 8–24.Google Scholar

13. Jerusalem, G, Hustinx, R, Beguin, Y, et al. Evaluation of therapy for lymphoma. Semin Nucl Med 2005; 35 (3): 186–196.Google Scholar

14. Lewandowski, RJ, Thurston, KG, Goin, JE, et al. 90Y Microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: Response to treatment at targeted doses of 135–150 Gy as measured by (18f) fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005; 16 (12): 1641–1651.Google Scholar

15. Tellez, C, Benson, AB 3rd, Lyster, MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998; 82 (7): 1250–1259.Google Scholar

16. Kulik, L, Carr, B, Mulcahy, M. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71–81.Google Scholar

17. Salem, R, Lewandowski, R, Roberts, C. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004; 15: 335–345.Google Scholar

18. Liu, DM, Salem, R, Bui, JT, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 2005; 16 (7): 911–935.Google Scholar

19. Rhee, TK, Omary, RA, Gates, V, et al. The effect of catheter-directed CT angiography on Yttrium-90 radioembolization treatment of hepatocellular carcinoma. J Vasc Interv Radiol 2005; 16 (8): 1085–1091.Google Scholar

20. Lewandowski, RJ, Sato, KT, Atassi, B, et al. Radioembolization with 90Y microspheres: Angiographic and technical considerations. Cardiovasc Intervent Radiol 2007; 30 (4): 571–592.Google Scholar

21. Wang, S, Bester, L, Burnes, J, et al. Clinical care and technical recommendations for 90 yttrium microsphere treatment of liver cancer. J Med Imaging Radiat Oncol 2010; 54: 178–187.Google Scholar

22. Kim, HC, Chung, JW, Lee, W, et al. Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiographics 2005; 25 Suppl 1: S25–S39.Google Scholar

23. Murthy, R, Nunez, R, Szklaruk, J, et al. Yttrium-90 micro-sphere therapy for hepatic malignancy: Devices, indications, technical considerations, and potential complications. Radiographics 2005; 25 Suppl 1: S41–S55.Google Scholar

24. Salem, R, Lewandowski, RJ, Sato, KT, et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol 2007; 10 (1): 12–29.Google Scholar

25. Geschwind, JF, Soulen, MC. Interventional Oncology: Principles and Practice. Cambridge, UK: Cambridge University Press; 2008, pp. 1103–1133.

26. SIRTeX Medical Training Manual. Lane Cove, Australia: SIRTeX Medical, 2005.

27. Salem, R, Thurston, KG, Carr, BI, et al. Yttrium-90 micro-spheres: Radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002; 13(suppl): S223–S229.Google Scholar

28. Ho, S, Lau, WY, Leung, TW, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997; 24 (3): 293–298.Google Scholar

29. Berger, MJ. Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. J Nucl Med 1971; Suppl 5: 5–23.Google Scholar

30. Snyder, W, Ford, M, Warner, G, et al. S Absorbed Dose Per Unit Cumulated Activity for Selected Radionuclides and Organs. New York: Society of Nuclear Medicine, 1975–1976.

31. Shi, S, Klotz, U. Proton pump inhibitors: An update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64: 935–951.Google Scholar

32. South, C, Meyer, M, Meis, G, et al. Yttrium-90 microsphere induced gastrointestinal tract ulceration. World J Surg Oncol 2008; 6: 93–97.Google Scholar

33. Salem, R, Lewandowski, RJ, Atassi, B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): Safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16 (12): 1627–1639.Google Scholar

34. Murthy, R, Brown, D, Salem, R. Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol 2007; 18: 553–561.Google Scholar

35. Sjoquest, K, Goldstein, D, Bester, L. A serious complication of selected internal radiation therapy: Case report and literature review. Oncologist 2010; 15: 830–835.Google Scholar

36. Lewandowski, R, Salem, R. Incidence of radiation cholecystitis in patients receiving Y-90 treatment for unresectable liver malignancies. J Vasc Interv Radiol 2004; 15 (2 pt 2): S162.Google Scholar

37. Wong, CY, Salem, R, Qing, F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: Comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 2004; 45 (11): 1892–1897.Google Scholar

38. Wong, CY, Salem, R, Raman, S, et al. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by (18F) FDG PET: A comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002; 29 (6): 815–820.Google Scholar

39. Geschwind, JF, Artemov, D, Abraham, S, et al. Chemoembolization of liver tumor in a rabbit model: Assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. J Vasc Interv Radiol 2000; 11 (10): 1245–1255.Google Scholar

40. Gray, B, Hazel, G Van, Hope, M, et al. Randomized trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12 (12): 1711–1720.Google Scholar

41. Hazel, G Van, Blackwell, A, Anderson, J, et al. Randomized phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin alone in advanced colorectal cancer. J Surg Oncol 2004; 88 (2): 78–85.Google Scholar

42. Sharma, R, Hazel, G Van, Morgan, B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007; 25 (9): 1099–1106.Google Scholar

43. Hazel, G Van, Pavlakis, N, Goldstein, D, et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 2009; 27 (25): 4089–4095.Google Scholar

44. Lim, L, Gibbs, P, Yip, D. A prospective evaluation of treatment with selective internal radiation therapy (SIR-Spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer 2005; 5: 132.Google Scholar

45. Hendlisz, A, den Eynde, M Van, Peeters, M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28 (23): 3687–3694.Google Scholar

46. Seidensticker, R, Denecke, T, Kraus, P, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 2012; 35 (5): 1066–1073.Google Scholar

47. Cosimelli, M, Golfieri, R, Cagol, P, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010; 103 (3): 324–331.Google Scholar

48. Kennedy, A, Coldwell, D, Nutting, C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006; 65 (2): 412–425.Google Scholar

49. Mulcahy, MF, Lewandowski, RJ, Ibrahim, SM, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 2009; 115 (9): 1849–1858.Google Scholar

50. Goin, JE, Dancey, JE, Hermann, GA, et al. Treatment of unresectable metastatic colorectal carcinoma to the liver with intrahepatic Y-90 microspheres: A dose-ranging study. World J Nucl Med 2003; 2: 216–225.Google Scholar

51. Hazel, GA Van, Heinemann, V, Sharma, NK, et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 2016; 34 (15): 1723–31.Google Scholar

52. Ruers, T, Punt, CJA, Coevorden, F Van, et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Oncol 2015; 33 (15) A3501. http://meetinglibrary.asco.org/content/151361-156 Google Scholar

Accessibility standard: Unknown

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

Accessibility compliance for the PDF of this chapter is currently unknown and may be updated in the future.